Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Multiple Myeloma

Trial Name: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).

Protocol ID: E1A11

Eligibility:

Eligibility:

Step 1 Randomization

  • Age 18 yrs. and older
  • Must meet required laboratory values
  • Patients must be diagnosed with symptomatic standard-risk multiple myeloma (SR-MM).
  • Patients with history of prior malignancy are eligible provided they were treated with curative intent and do not require active therapy (currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma “in situ” of the cervix or breast are not included).
  • Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 4 weeks after stopping treatment.
  • The following patients will be excluded as this study involves an agent that may have genotoxic, mutagenic and teratogenic effects: pregnant women, nursing women.

Step 2 Randomization

  • Patients must not have experienced progression on Step 1 induction therapy.
  • Patients must not have received any non-protocol therapy outside of the assigned induction therapy.
  • Must meet required laboratory values
  • Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 4 weeks after stopping treatment.

The following patients will be excluded as this study involves an agent that may have genotoxic, mutagenic and teratogenic effects: pregnant women, nursing women.

Enrollment: 756 will be enrolled

Benefits:

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope the treatments used in the study will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about these drugs as a treatment for myeloma. This information could help future cancer patients.

Contact:

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Feb 24, 2014

Updated: May 21, 2014

« Return to Trials